Clinical Data Company Description
Clinical Data's products and services are central to health and life. The drug development company focuses on late-stage drug candidates with an emphasis on treatments for cancer, as well as cardiovascular, and psychiatric disorders. Following a series of acquisitions, divestitures, and reorganizations, Clinical Data has focused its operations around its PGxHealth division, which develops and sells genetic tests and engages in drug discovery research. It performs the bulk of its research in three labs in Virginia and Connecticut, however the company operates globally and holds US and foreign patents. The publicly-traded company is led by CEO Drew Fromkin. Chairman Randal Kirk owns nearly 45% of Clinical Data.
View the Comprehensive Company Description for Clinical Data
The Company Description provides a historical perspective of Clinical Data's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Clinical Data's evolution in the marketplace.
